Pfizer’s 7% Dividend: Temptation with a Warning Label

PFE“>

Loading widget...

When high yield signals high risk

A 7% yield is a red flag in a market full of green. Pfizer trades at 8.1 times forward earnings-a number that screams “caution.” Earnings are projected to decline 3% annually through 2029. Peers like Johnson & Johnson (2.9%) and Merck (3.9%) offer lower yields but stronger balance sheets. AbbVie’s 3.1% isn’t bad either. These companies trade stability for greed. Pfizer’s dividend is a gamble that management can outwit patent cliffs and pipeline failures. It’s a bet with no guaranteed payout.

The dividend is safe through 2026, perhaps with token raises. But long-term? The board will face choices. A cut isn’t imminent, but growth is a fantasy. Buying Pfizer for its dividend is betting against entropy itself. The 7% yield is a warning label, not a promise. So it goes.

The payout will survive the next few years, maybe with small increases. But the long-term outlook is a question mark. Pfizer’s 7% dividend is less a gift than a dare. Investors are invited to dance with the devil-on a sinking ship. 🚩

Read More

2025-09-01 13:20